共 50 条
- [1] Pembrolizumab plus lenvatinib (P plus L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 422 - 422Yan, KevinRane, PratikSchmidinger, ManuelaPeer, AvivitDruyts, EricBurgents, Joseph E.Sundaram, Murali
- [2] Pembrolizumab plus axitinib (P plus A) versus other first-line (1L) systemic therapies for advanced/metastatic clear-cell renal cell carcinoma (ccmRCC) by IMDC Risk Status - a network meta-analysis (NMA)JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7McGovern, IanShirali, RohanSimon, AndrewZhong, YichenPerini, RodolfoLorenzi, MariaAdejoro, Oluwakayode
- [3] PEMBROLIZUMAB PLUS AXITINIB (P plus A) VERSUS OTHER FIRST-LINE (1L) SYSTEMIC THERAPIES FOR ADVANCED/METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCMRCC) - A NETWORK META-ANALYSIS (NMA)VALUE IN HEALTH, 2019, 22 : S444 - S444McGovern, ISimon, A.Shirali, R.Zhong, Y.Perini, R.Lorenzi, M.Adejoro, O.
- [4] Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 482 - 482Gruenwald, ViktorWinquist, EricPeer, AvivitSchmidinger, ManuelaProcopio, GiuseppeBarthelemy, PhilippeLee, Jae-LyunRudman, SarahKadambi, AnanthPandey, AnujaNeupane, BinodFahrbach, KylePurushotham, SnehaJones, MichaelEgodage, SonyaKashyap, AnanthHauck, WendyPan, Janice
- [5] NETWORK META-ANALYSIS (NMA) TO ASSESS COMPARATIVE EFFICACY OF LENVATINIB PLUS PEMBROLIZUMAB COMPARED WITH OTHER FIRST-LINE TREATMENTS FOR MANAGEMENT OF ADVANCED RENAL CELL CARCINOMA (ARCC)VALUE IN HEALTH, 2022, 25 (07) : S310 - S310Kadambi, A.Pandey, A.Neupane, B.Fahrbach, K.Purushotham, S.Jones, M.Egodage, S.Kashyap, A.Pan, J.
- [6] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMAJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447Choueiri, ToniPlimack, ElizabethPowles, ThomasVoss, MartinGurney, HowardSilverman, RachelPerini, RodolfoRodriguez-Lopez, KarlaRini, Brian
- [7] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)Choueiri, Toni K.Plimack, Elizabeth R.Powles, ThomasVoss, Martin H.Gurney, HowardSilverman, Rachel KlossPerini, Rodolfo F.Rodriguez-Lopez, KarlaRini, Brian I.
- [8] MULTIDIMENSIONAL TREATMENT EFFECT NETWORK META-ANALYSIS TO ESTIMATE SURVIVAL OF THERAPIES FOR PATIENTS WITH FIRST-LINE (1L) ADVANCED OR METASTATIC RENAL CELL CARCINOMA (ARCC) IN FRANCEVALUE IN HEALTH, 2022, 25 (01) : S25 - S25Gittfried, A. M., VLambton, M.Nickel, K.May, J. R.Branchoux, S.Kroep, S.
- [9] Network meta-analysis (NMA) of first-line advanced renal cell carcinoma (1L aRCC) treatments: Development of a decision algorithm for fractional polynomial (FP) model selection.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)McGregor, Bradley AlexanderPetersohn, SvenjaKlijn, SvenMay, JessicaEjzykowicz, FlaviaKurt, MuratDyer, MatthewKroep, SonjaGeorge, Saby
- [10] Characteristics of patients with advanced renal cell carcinoma (aRCC) who received first-line (1L) nivolumab plus cabozantinib (NIVO plus CABO), pembrolizumab plus lenvatinib (PEM plus LEN), or nivolumab (NIVO) monotherapy in the real-world (RW) settingCANCER RESEARCH, 2024, 84 (06)Zarrabi, Kevin K.Miron, BenjaminYin, XinRosenblatt, LisaGuttenplan, Sarah B.John, WilliamMiller, Taavy A.Asgarisabet, ParisaPathak, PrathameshAhlquist, MonicaGash, Yul BrianGeynisman, Daniel M.